Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC

NCT02129699 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT02129699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02129699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 3
Overall status
Terminated
Start date
January 6, 2015
Completion date
February 29, 2020
Enrollment
595 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer non-small cell stage iv